Titre : Polyangéite microscopique

Polyangéite microscopique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Pre-Exposure Prophylaxis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Polyangéite microscopique : Questions médicales les plus fréquentes", "headline": "Polyangéite microscopique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Polyangéite microscopique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-03", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Polyangéite microscopique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "url": "https://questionsmedicales.fr/mesh/D056648", "about": { "@type": "MedicalCondition", "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "code": { "@type": "MedicalCode", "code": "D056648", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.111.193" } } }, "about": { "@type": "MedicalCondition", "name": "Polyangéite microscopique", "alternateName": "Microscopic Polyangiitis", "code": { "@type": "MedicalCode", "code": "D055953", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jason Jungsik Song", "url": "https://questionsmedicales.fr/author/Jason%20Jungsik%20Song", "affiliation": { "@type": "Organization", "name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea." } }, { "@type": "Person", "name": "Sang-Won Lee", "url": "https://questionsmedicales.fr/author/Sang-Won%20Lee", "affiliation": { "@type": "Organization", "name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea. sangwonlee@yuhs.ac." } }, { "@type": "Person", "name": "Sung Soo Ahn", "url": "https://questionsmedicales.fr/author/Sung%20Soo%20Ahn", "affiliation": { "@type": "Organization", "name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea." } }, { "@type": "Person", "name": "Yong-Beom Park", "url": "https://questionsmedicales.fr/author/Yong-Beom%20Park", "affiliation": { "@type": "Organization", "name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea." } }, { "@type": "Person", "name": "Taejun Yoon", "url": "https://questionsmedicales.fr/author/Taejun%20Yoon", "affiliation": { "@type": "Organization", "name": "Department of Medical Science, College of Medicine, BK21 Plus Project, Yonsei University, Seoul, Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England.", "datePublished": "2023-02-10", "url": "https://questionsmedicales.fr/article/36773896", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jinf.2023.01.033" } }, { "@type": "ScholarlyArticle", "name": "Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients.", "datePublished": "2023-01-31", "url": "https://questionsmedicales.fr/article/36759280", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.transci.2023.103648" } }, { "@type": "ScholarlyArticle", "name": "Current Perspectives on the Determinants of Acceptability of Pre-Exposure Prophylaxis and Nonoccupational Post-Exposure Prophylaxis among People at Risk for HIV: A Scoping Review.", "datePublished": "2022-10-02", "url": "https://questionsmedicales.fr/article/36231904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph191912605" } }, { "@type": "ScholarlyArticle", "name": "Knowledge and attitudes of HIV pre-exposure prophylaxis among nurses in South Africa.", "datePublished": "2023-09-19", "url": "https://questionsmedicales.fr/article/37916728", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4102/phcfm.v15i1.4086" } }, { "@type": "ScholarlyArticle", "name": "Prioritising the values of potential users to promote uptake of HIV pre-exposure prophylaxis.", "datePublished": "2023-08-10", "url": "https://questionsmedicales.fr/article/37573870", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2352-3018(23)00171-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Maladies auto-immunes", "item": "https://questionsmedicales.fr/mesh/D001327" }, { "@type": "ListItem", "position": 4, "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "item": "https://questionsmedicales.fr/mesh/D056648" }, { "@type": "ListItem", "position": 5, "name": "Polyangéite microscopique", "item": "https://questionsmedicales.fr/mesh/D055953" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Polyangéite microscopique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Polyangéite microscopique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Polyangéite microscopique", "description": "Comment diagnostiquer la polyangéite microscopique ?\nQuels tests sanguins sont utilisés ?\nQuels symptômes orientent vers ce diagnostic ?\nLa biopsie est-elle toujours nécessaire ?\nQuels examens d'imagerie sont recommandés ?", "url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Pre-Exposure+Prophylaxis&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Polyangéite microscopique", "description": "Quels sont les symptômes courants ?\nLa polyangéite microscopique cause-t-elle des problèmes rénaux ?\nY a-t-il des symptômes respiratoires associés ?\nLes symptômes varient-ils d'un patient à l'autre ?\nPeut-on avoir des symptômes neurologiques ?", "url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Pre-Exposure+Prophylaxis&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Polyangéite microscopique", "description": "Peut-on prévenir la polyangéite microscopique ?\nQuels conseils de mode de vie peuvent aider ?\nLes vaccinations sont-elles recommandées ?\nFaut-il éviter certains médicaments ?\nLe suivi médical est-il important ?", "url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Pre-Exposure+Prophylaxis&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Polyangéite microscopique", "description": "Quels traitements sont utilisés pour cette maladie ?\nLes corticostéroïdes sont-ils efficaces ?\nCombien de temps dure le traitement ?\nY a-t-il des effets secondaires aux traitements ?\nDes traitements biologiques sont-ils disponibles ?", "url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Pre-Exposure+Prophylaxis&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Polyangéite microscopique", "description": "Quelles sont les complications possibles ?\nLa polyangéite microscopique peut-elle être mortelle ?\nComment prévenir les complications ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme ?", "url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Pre-Exposure+Prophylaxis&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Polyangéite microscopique", "description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque ?\nLes infections peuvent-elles déclencher la maladie ?\nLe sexe joue-t-il un rôle dans le risque ?\nDes facteurs environnementaux sont-ils impliqués ?", "url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Pre-Exposure+Prophylaxis&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la polyangéite microscopique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des analyses sanguines, des biopsies et des examens d'imagerie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent la recherche d'anticorps anti-MPO et des marqueurs d'inflammation." } }, { "@type": "Question", "name": "Quels symptômes orientent vers ce diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Symptômes comme la fatigue, la fièvre, et des douleurs articulaires peuvent indiquer la maladie." } }, { "@type": "Question", "name": "La biopsie est-elle toujours nécessaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, la biopsie n'est pas toujours nécessaire, mais elle peut confirmer le diagnostic." } }, { "@type": "Question", "name": "Quels examens d'imagerie sont recommandés ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les IRM et les scanners peuvent aider à visualiser les atteintes organiques." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, fièvre, éruptions cutanées et douleurs musculaires." } }, { "@type": "Question", "name": "La polyangéite microscopique cause-t-elle des problèmes rénaux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner une insuffisance rénale aiguë due à l'inflammation des vaisseaux rénaux." } }, { "@type": "Question", "name": "Y a-t-il des symptômes respiratoires associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la toux et des douleurs thoraciques peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'un patient à l'autre ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes neurologiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des maux de tête ou des troubles de la vision peuvent apparaître." } }, { "@type": "Question", "name": "Peut-on prévenir la polyangéite microscopique ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé." } }, { "@type": "Question", "name": "Quels conseils de mode de vie peuvent aider ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain, éviter le tabac et gérer le stress peuvent être bénéfiques." } }, { "@type": "Question", "name": "Les vaccinations sont-elles recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent aider à prévenir certaines infections, surtout sous traitement immunosuppresseur." } }, { "@type": "Question", "name": "Faut-il éviter certains médicaments ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent aggraver la maladie, il est donc important de consulter un médecin." } }, { "@type": "Question", "name": "Le suivi médical est-il important ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier permet de surveiller l'évolution de la maladie et d'ajuster le traitement." } }, { "@type": "Question", "name": "Quels traitements sont utilisés pour cette maladie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs pour réduire l'inflammation." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent efficaces pour contrôler l'inflammation et soulager les symptômes." } }, { "@type": "Question", "name": "Combien de temps dure le traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement varie, mais peut durer plusieurs mois à plusieurs années." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les effets secondaires peuvent inclure des infections, des troubles digestifs et des problèmes osseux." } }, { "@type": "Question", "name": "Des traitements biologiques sont-ils disponibles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements biologiques comme le rituximab peuvent être utilisés dans certains cas." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance rénale, les infections et les problèmes pulmonaires." } }, { "@type": "Question", "name": "La polyangéite microscopique peut-elle être mortelle ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement approprié, elle peut entraîner des complications graves et potentiellement mortelles." } }, { "@type": "Question", "name": "Comment prévenir les complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement précoce et un suivi régulier sont essentiels pour prévenir les complications." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent inclure des problèmes rénaux chroniques et des troubles pulmonaires." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la polyangéite microscopique est plus fréquente chez les adultes âgés de 50 à 70 ans." } }, { "@type": "Question", "name": "Les infections peuvent-elles déclencher la maladie ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections virales ou bactériennes peuvent être des déclencheurs." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la maladie est légèrement plus fréquente chez les hommes que chez les femmes." } }, { "@type": "Question", "name": "Des facteurs environnementaux sont-ils impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains produits chimiques ou médicaments peut augmenter le risque." } } ] } ] }

Sources (10000 au total)

HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England.

HTLV-1 is predominantly a sexually-transmitted infection but testing is not mentioned in HIV-PrEP guidelines. We ascertained HTLV-1/HTLV-2 seroprevalence amongst HIV-PrEP users in England.... An unlinked anonymous seroprevalence study.... Amongst 2015 HIV-PrEP users, 95% were men, 76% of white ethnicity and 83% had been born in Europe. There were no HTLV-1/HTLV-2 seropositive cases (95% confidence interval 0% - 0.18%).... There were no HTLV positive cases, likely reflecting the demographic of mostly white and European-born individuals. Similar studies are needed worldwide to inform public health recommendations for HIV...

Current Perspectives on the Determinants of Acceptability of Pre-Exposure Prophylaxis and Nonoccupational Post-Exposure Prophylaxis among People at Risk for HIV: A Scoping Review.

Pre-exposure prophylaxis (PrEP) and nonoccupational post-exposure prophylaxis (nPEP) were found to be effective HIV biomedical interventions. However, several barriers to acceptance of these intervent...

Knowledge and attitudes of HIV pre-exposure prophylaxis among nurses in South Africa.

Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) has shown efficacy and effectiveness in populations who practise high-risk sexual activity. Nurses' knowledge and positive attitudes ... This study aimed to investigate the knowledge of and attitudes towards PrEP among nurses in primary health care facilities.... The study was conducted in 10 health facilities that offer comprehensive services in Tshwane, South Africa.... A cross-sectional survey assessed the knowledge of and attitudes towards PrEP among 114 nurses. Univariate, bivariate and logistic regressions were performed to estimate odds ratios and to determine w... Majority of the study sample consisted of female nurses (92.1%), and most respondents (68%) had moderate PrEP knowledge. Logistic regression showed that age and education were not associated with high... This study found that there is a need to strengthen the dissemination of information about PrEP, and nurses in South Africa require training to improve their knowledge of and attitudes towards PrEP.Co...

Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa.

HIV endpoint-driven clinical trials increasingly provide oral pre-exposure prophylaxis (PrEP) as standard of prevention during the trial, however, among participants desiring to continue using PrEP at... We conducted one-time, semi-structured, face-to-face, in-depth interviews with 13 women from Durban, South Africa, from November to December 2021. We interviewed women who initiated oral PrEP as part ... Of the 13 women, six accessed oral PrEP post-trial exit, but five later discontinued. The remaining seven women did not access PrEP. Barriers to post-trial PrEP access and continued use included PrEP ... We identified several barriers to post-trial PrEP access. Strategies to enhance PrEP access such as a reduction in waiting queues, convenient facility operating hours, and making PrEP more widely avai...

Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis.

We describe the first case of HIV-1 infection in the setting of long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis to occur in the real world.... Case report.... Electronic medical records were reviewed to assess patient history and CAB-LA administration details. Plasma fourth-generation HIV-1/2 Ag/Ab combination immunoassay and HIV-1 RNA quantitative PCR were... We report a 28-year-old sex-diverse person assigned male at birth who acquired HIV-1 infection 91 days after transitioning from tenofovir alafenamideemtricitabine to CAB-LA despite on-time dosing and ... This patient's history suggests HIV infection despite on-time and appropriate CAB-LA injections. To our knowledge, this is the first case of CAB-LA pre-exposure prophylaxis failure outside the setting...